BRPI0916442A2 - dosagem terapêutica de uma neuregulina ou de uma subsequência da mesma para tratamento ou profilaxia de insuficiência cardíaca - Google Patents

dosagem terapêutica de uma neuregulina ou de uma subsequência da mesma para tratamento ou profilaxia de insuficiência cardíaca

Info

Publication number
BRPI0916442A2
BRPI0916442A2 BRPI0916442-1A BRPI0916442A BRPI0916442A2 BR PI0916442 A2 BRPI0916442 A2 BR PI0916442A2 BR PI0916442 A BRPI0916442 A BR PI0916442A BR PI0916442 A2 BRPI0916442 A2 BR PI0916442A2
Authority
BR
Brazil
Prior art keywords
neuregulin
prophylaxis
follow
treatment
heart failure
Prior art date
Application number
BRPI0916442-1A
Other languages
English (en)
Portuguese (pt)
Inventor
Caggiano Anthony
Ganguly Anindita
Iaci Jennifer
Parry Tom
Original Assignee
Acorda Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acorda Therapeutics, Inc. filed Critical Acorda Therapeutics, Inc.
Publication of BRPI0916442A2 publication Critical patent/BRPI0916442A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1883—Neuregulins, e.g.. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BRPI0916442-1A 2008-07-17 2009-07-17 dosagem terapêutica de uma neuregulina ou de uma subsequência da mesma para tratamento ou profilaxia de insuficiência cardíaca BRPI0916442A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13517108P 2008-07-17 2008-07-17
US61/135,171 2008-07-17
PCT/US2009/004130 WO2010030317A2 (en) 2008-07-17 2009-07-17 Therapeutic dosing of a neuregulin or a subsequence thereof for treatment or prophylaxis of heart failure

Publications (1)

Publication Number Publication Date
BRPI0916442A2 true BRPI0916442A2 (pt) 2018-06-19

Family

ID=42005671

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0916442-1A BRPI0916442A2 (pt) 2008-07-17 2009-07-17 dosagem terapêutica de uma neuregulina ou de uma subsequência da mesma para tratamento ou profilaxia de insuficiência cardíaca

Country Status (13)

Country Link
US (5) US20110166068A1 (OSRAM)
EP (3) EP2320933B1 (OSRAM)
JP (5) JP5797112B2 (OSRAM)
CN (3) CN107019794B (OSRAM)
AU (3) AU2009292216B2 (OSRAM)
BR (1) BRPI0916442A2 (OSRAM)
CA (1) CA2731113A1 (OSRAM)
DK (2) DK2320933T3 (OSRAM)
ES (2) ES2664394T3 (OSRAM)
MX (2) MX384378B (OSRAM)
PL (2) PL2320933T3 (OSRAM)
RU (4) RU2536938C2 (OSRAM)
WO (1) WO2010030317A2 (OSRAM)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009292216B2 (en) 2008-07-17 2015-03-05 Acorda Therapeutics, Inc. Therapeutic dosing of a neuregulin or a subsequence thereof for treatment or prophylaxis of heart failure
WO2010019275A2 (en) 2008-08-15 2010-02-18 Acorda Therapeutics, Inc. Compositions and methods for treatment during non-acute periods following cns neurological injury
WO2010060265A1 (en) * 2008-11-28 2010-06-03 Zensun (Shanghai) Science & Technology Limited Neuregulin peptides and their use
KR101933543B1 (ko) 2009-10-14 2018-12-28 아코르다 쎄라퓨틱스 인코포레이티드 말초 신경 손상을 치료하기 위한 뉴레귤린의 용도
WO2013053076A1 (en) * 2011-10-10 2013-04-18 Zensun （Shanghai）Science & Technology Limited Compositions and methods for treating heart failure
CN104321072A (zh) * 2012-03-30 2015-01-28 阿寇达医疗有限公司 神经调节蛋白在治疗外周神经损伤中的应用
EP2964249A1 (en) * 2013-03-06 2016-01-13 Acorda Therapeutics, Inc. Therapeutic dosing of a neuregulin or a fragment thereof for treatment or prophylaxis of heart failure
BR112015029293A2 (pt) 2013-05-22 2018-04-24 Zensun Shanghai Science & Tech Ltd método e kit para prevenir, tratar ou retardar uma doença ou distúrbio cardiovascular em um mamífero
CN110946993A (zh) 2014-01-03 2020-04-03 上海泽生科技开发股份有限公司 纽兰格林制剂的配方
CN105561298A (zh) 2014-10-17 2016-05-11 上海泽生科技开发有限公司 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物
CA2999301A1 (en) 2015-09-25 2017-03-30 Douglas B. Sawyer Methods for treating cardiac injury
EP3445386B1 (en) * 2016-04-19 2020-08-26 Leibniz-Institut für Alternsforschung - Fritz-Lipmann-Institut e.V. (FLI) Neuregulin for the treatment and/or prevention of tumors of the nervous system
CN110835368A (zh) * 2018-08-15 2020-02-25 上海泽生科技开发股份有限公司 神经调节蛋白多肽片段及其用途
AR121035A1 (es) 2019-04-01 2022-04-13 Lilly Co Eli Compuestos de neuregulina-4 y métodos de uso
US20230057622A1 (en) * 2019-09-16 2023-02-23 Zensun (Shanghai) Science & Technology, Co., Ltd. Recombinant Human Neuregulin Derivatives and Use Thereof
WO2023070078A1 (en) * 2021-10-22 2023-04-27 The Research Institute At Nationwide Children's Hospital Neuregulin for protection against respiratory viral infection and post-viral disease

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530109A (en) 1991-04-10 1996-06-25 Ludwig Institute For Cancer Research DNA encoding glial mitogenic factors
US5716930A (en) 1991-04-10 1998-02-10 Ludwig Institute For Cancer Research Glial growth factors
US7115554B1 (en) * 1993-05-06 2006-10-03 Acorda Therapeutics, Inc. Methods of increasing myotube formation or survival or muscle cell mitogenesis differentiation or survival using neuregulin GGF III
US7037888B1 (en) 1992-04-03 2006-05-02 Acorda Therapeutics, Inc. Methods for treating muscle diseases and disorders
US6087323A (en) 1992-04-03 2000-07-11 Cambridge Neuroscience, Inc. Use of neuregulins as modulators of cellular communication
US5811098A (en) * 1992-11-24 1998-09-22 Bristol-Myers Squibb Company Antibodies to HER4, human receptor tyrosine kinase
US5912326A (en) 1995-09-08 1999-06-15 President And Fellows Of Harvard College Cerebellum-derived growth factors
US6136558A (en) * 1997-02-10 2000-10-24 Genentech, Inc. Heregulin variants
US6051401A (en) 1998-07-28 2000-04-18 Bayer Corporation Methods and constructs for protein expression
EP1674107B8 (en) 1998-09-25 2017-01-25 Cubist Pharmaceuticals LLC Use of daptomycin
AUPP785098A0 (en) * 1998-12-21 1999-01-21 Victor Chang Cardiac Research Institute, The Treatment of heart disease
US6635249B1 (en) * 1999-04-23 2003-10-21 Cenes Pharmaceuticals, Inc. Methods for treating congestive heart failure
CN1138785C (zh) * 1999-06-04 2004-02-18 周明东 生长因子神经调节蛋白及其类似物的新应用
AU1916301A (en) 1999-11-12 2001-06-06 Children's Medical Center Corporation Methods for administration of therapeutic agents on an antiangiogenic schedule
CA2409996C (en) 2000-05-23 2016-03-01 Cenes Pharmaceuticals, Inc. Nrg-2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
CU23157A1 (es) * 2001-01-03 2006-07-18 Ct Ingenieria Genetica Biotech COMPOSICION FARMACéUTICA PARA EL TRATAMIENTO DEL DANO TISULAR DEBIDO A FALTA DE IRRIGACION SANGUINEA ARTERIAL
AU2003210549A1 (en) 2002-01-18 2003-09-02 Chiron Corporation Combination il-2/anti-herz antibody therapy for cancers characterized by overexpression of the her2 receptor protein
WO2003099320A1 (en) * 2002-05-24 2003-12-04 Zensun (Shanghai) Sci-Tech.Ltd Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
US20070032557A1 (en) * 2005-02-18 2007-02-08 Matti Kivikko Method for administering levosimendan
WO2006101691A1 (en) 2005-03-23 2006-09-28 Pfizer Products Inc. Therapy of prostate cancer with ctla4 antibodies and hormonal therapy
US7776817B2 (en) 2005-09-02 2010-08-17 Morehouse School Of Medicine Neuregulins for prevention and treatment of damage from acute assault on vascular and neuronal tissue and as regulators of neuronal stem cell migration
US20070213264A1 (en) * 2005-12-02 2007-09-13 Mingdong Zhou Neuregulin variants and methods of screening and using thereof
EP3363455A1 (en) 2005-12-30 2018-08-22 Zensun (Shanghai) Science & Technology, Co., Ltd. Extended release of neuregulin for improved cardiac function
RU2530650C2 (ru) 2008-02-29 2014-10-10 Акорда Терапьютикс, Инк. Способ обеспечения требуемых уровней фактора 2 роста глии в плазме
AU2009292216B2 (en) 2008-07-17 2015-03-05 Acorda Therapeutics, Inc. Therapeutic dosing of a neuregulin or a subsequence thereof for treatment or prophylaxis of heart failure
KR101933543B1 (ko) 2009-10-14 2018-12-28 아코르다 쎄라퓨틱스 인코포레이티드 말초 신경 손상을 치료하기 위한 뉴레귤린의 용도
CA2845198A1 (en) 2010-08-13 2012-02-16 Georgetown University Ggf2 and methods of use
CN104321072A (zh) 2012-03-30 2015-01-28 阿寇达医疗有限公司 神经调节蛋白在治疗外周神经损伤中的应用

Also Published As

Publication number Publication date
JP2017200949A (ja) 2017-11-09
MX2011000696A (es) 2011-07-29
JP5797112B2 (ja) 2015-10-21
HK1256637A1 (en) 2019-09-27
RU2698090C2 (ru) 2019-08-22
RU2020111236A (ru) 2021-09-21
US20180280477A1 (en) 2018-10-04
EP2320933B1 (en) 2017-12-27
JP2015129137A (ja) 2015-07-16
CN107019794A (zh) 2017-08-08
JP6189879B2 (ja) 2017-08-30
EP3338791A1 (en) 2018-06-27
US20110166068A1 (en) 2011-07-07
US20130324466A1 (en) 2013-12-05
US20160113999A1 (en) 2016-04-28
AU2009292216A1 (en) 2010-03-18
RU2536938C2 (ru) 2014-12-27
ES2664394T3 (es) 2018-04-19
JP2019196370A (ja) 2019-11-14
AU2015202877A1 (en) 2015-06-18
WO2010030317A2 (en) 2010-03-18
EP3338791B1 (en) 2019-09-18
EP2320933A4 (en) 2013-02-27
ES2763184T3 (es) 2020-05-27
MX384378B (es) 2025-03-14
US9956266B2 (en) 2018-05-01
JP2022023208A (ja) 2022-02-07
PL2320933T3 (pl) 2018-07-31
CN107019794B (zh) 2021-03-12
AU2009292216B2 (en) 2015-03-05
CN104623633A (zh) 2015-05-20
US20200009228A1 (en) 2020-01-09
EP2320933A1 (en) 2011-05-18
AU2017203528A1 (en) 2017-06-15
EP3632459A1 (en) 2020-04-08
DK2320933T3 (en) 2018-04-16
RU2011105821A (ru) 2012-08-27
RU2020111236A3 (OSRAM) 2021-09-21
JP2011528353A (ja) 2011-11-17
PL3338791T3 (pl) 2020-04-30
AU2015202877B2 (en) 2017-03-09
CN102159236A (zh) 2011-08-17
US9198951B2 (en) 2015-12-01
DK3338791T3 (da) 2019-12-16
RU2014141514A (ru) 2016-05-10
US11235031B2 (en) 2022-02-01
RU2719199C1 (ru) 2020-04-17
CA2731113A1 (en) 2010-03-18

Similar Documents

Publication Publication Date Title
BRPI0916442A2 (pt) dosagem terapêutica de uma neuregulina ou de uma subsequência da mesma para tratamento ou profilaxia de insuficiência cardíaca
LTC2137143I2 (lt) Pleuromutilino dariniai, skirti mikrobų sukeltų ligų gydymui
BRPI1009034A2 (pt) composição farmacêutica e método para o tratamento ou profilaxia de uma infecção viral ou doença associada a mesma
BRPI1012116A2 (pt) composição farmacêutica para o tratamento de doenças cardíacas
BRPI0909985A2 (pt) Composição farmacêutica e método para o tratamento ou profilaxia de uma infecção viral ou doença associada à mesma
SMT201600055B (it) Composizione farmaceutica per il trattamento o la prevenzione del glaucoma
CO7020879A2 (es) Miméticos de apelina sintéticos para el tratamiento de insuficiencia cardíaca
HUE045367T2 (hu) Kombinált terápia diabétesz kezelésére
CO6910184A2 (es) Nuevos compuestos para tratamiento de enfermedades asociadas con proteinas amiloides o tipo amiloide
BRPI0915105A2 (pt) composto de 2,4'-biripidinila como inibidores da proteína cinase d úteis para o tratamento de ia insuficiência cardíaca e cancer
ZA201303960B (en) Novel compounds as respiratory stimulants for treatment of breathing control disorders or diseases
BRPI0807987A2 (pt) Terapia de combinação para tratamento de distúrbios imunes.
IL241133A0 (en) Preparations containing a medicinal dose of neuragiolin or a fragment thereof for the treatment or prevention of heart failure
PT2582366E (pt) Combinação terapêutica para o tratamento da dor
PT2627345E (pt) Formulações para o tratamento de distúrbios das vias respiratórias superiores
BRPI0907950A2 (pt) Tratamento de hiperglicemia com 25-hidroxivitamina d3
WO2010132347A9 (en) Docosahexaenoic acid for the treatment of heart failure
BR112012032721A2 (pt) compostos heterocíclicos, sua preparação e sua aplicação terapêutica
CO6801718A2 (es) Composición terapéutica para el tratamiento de glioblastoma
BRPI1011768A8 (pt) agentes para o tratamento e/ou profilaxia de um distúrbio, e de uma doença, composição farmacêutica, kit, derivado de tiazol, composto, combinação, e, uso de um derivado de tiazol
PT2525796T (pt) Solução aquosa incluindo 3-quinuclidinonas para o tratamento de doenças hiperproliferativas, auto-imunes e cardíacas
SG11201403265VA (en) Medical composition for preventing or treating amyloid β peptide related diseases or conditions
EE201300004A (et) Kombineeritud ravimkoostis sdame-veresoonkonnaga seotud haiguste v?i seisundite raviks
EP2185162A4 (en) POLYMER THERAPY FOR THE TREATMENT OF CHRONIC MICROVASCULAR DISEASES
MX355015B (es) Uso de hidroxamatos de indolilo e indolinilo para tratar insuficiencia cardiaca o lesión neuronal.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 14A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2731 DE 09-05-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.